January 15, 2025 03:17 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Akhilesh Yadav takes holy dip in Ganga on Makar Sankranti | Sharad Pawar accuses Amit Shah of not maintaining his post's decorum after latter's treachery jibe | India 'strongly takes' up matter with Moscow after Kerala man dies fighting for Russia | Delhi court slams cop for manipulating evidence in 2020 riots case, acquits accused who was falsely implicated | Maha Kumbh in Prayagraj: Ten million devotees brave winter chills to take holy dip in Sangam for first 'Amrit Snan' | Five Bangladeshi nationals illegally staying in Kolkata's suburb arrested | PM Modi participates in Lohri celebrations in Delhi's Naraina | 'Pollution, corruption, inflation are on rise': Rahul Gandhi slams Arvind Kejriwal ahead of Delhi assembly polls | AAP accuses BJP of manipulating voters' list ahead of Delhi polls, election officer responds | Millions of Hindu devotees gather in UP's Prayagraj as world's largest pilgrimage Maha Kumbh Mela begins today
Polio Vaccine
Photo Courtesy: WIkimedia Commons

WHO grants pre-qualification status to Hyderabad-based pharms new oral polio vaccine for immunisation

| @indiablooms | Jul 31, 2024, at 11:37 pm

Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company on Tuesday announced that the World Health Organisation (WHO) has granted Pre-qualification (PQ) status to their Novel Oral Polio Vaccine type 2 (nOPV2).

nOPV2 is the 10th pre-qualified vaccine of BE.

This next-generation live, attenuated oral vaccine significantly reduces the risk of circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks and it is aimed at immunisation in countries that are affected by cVDPV2 outbreaks, which is a crucial moment in the fight against polio.

The persistent threat of circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks can be tackled with the use of nOPV2 as the vaccine of choice.

With its improved genetic stability, nOPV2 has a significantly decreased chance of seeding new outbreaks in low-immunity environments as against its predecessor, the Sabin poliovirus type 2 (mOPV2) vaccine.

Extensive clinical trials have rigorously evaluated the safety and immunogenicity of nOPV2, leading to promising results published in The Lancet (2019-2024).

Furthermore, the vaccine's real-world deployment in outbreak regions has shown that it can significantly decrease the incidence of cVDPV2 outbreaks, safeguarding communities from the ravages of polio.

BE has become an important player in the production of the nOPV2 vaccine, having been selected for a grant from the Bill and Melinda Gates Foundation (BMGF) to assist in meeting the growing global demand.

In collaboration with PT Bio Farma (PTB) in Indonesia, the first manufacturer of the nOPV2 vaccine to receive WHO Pre-Qualification in January 2024, BE said it has successfully received technology from PTB and qualified large-scale manufacturing facilities that produce more than 500 million doses of nOPV2 vaccine annually.

BE has been approved by the Indian regulatory authorities to manufacture the vaccine for export purposes.

Mahima Datla, Managing Director, Biological E. Limited, said, "We are pleased to be a part of the global effort to eradicate polio. Our collective quest to eradicate polio marks a significant milestone with the WHO pre-qualification of nOPV2. This vaccine has been specifically designed to address concerns about Vaccine-Associated Paralytic Polio (VAPP), which has occurred in approximately 2 to 4 cases per million births with the traditional OPV due to the vaccine virus reverting to a virulent form."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Close menu